IndustryCompany release
CorMedix posts $54.5M Q3 revenue, narrows 2026 EBITDA guidance and details Heron asset deal
🇺🇸 CorMedix Inc. (CRMD) · Mon 16 Nov 2026
On its 12 November earnings call, CorMedix also discussed the CMS 2027 ESRD final rule for DefenCath and the FDA's priority review of a REZZAYO sNDA.
CorMedix reported third-quarter revenue of $54.5M and cash of $355M on its earnings call on 12 November 2026. The company narrowed its full-year 2026 adjusted EBITDA guidance to a range of $130M to $140M.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): CorMedix Inc. ↗
Article written by VigiEye from the official source (CorMedix Inc.). Claims are the company's own. AI-assisted; check the source before acting.
More Industry
All →
Merck KGaA to acquire Rapid Micro Biosystems; Q3 revenue rises to $9.5M
🇺🇸 Rapid Micro Biosystems, Inc. (RPID) · Mon 16 Nov 2026
Microbot Medical Q3 revenue falls to $72,000 as gross margin turns negative
🇺🇸 Microbot Medical Inc. (MBOT) · Mon 16 Nov 2026
TOYO Co. reports lower Q3 revenue and net income, but higher nine-month sales
TOYO Co., Ltd (TOYO) · Mon 16 Nov 2026
Eocene unit and Barcode Nanotech develop tumour-targeted nanoparticle form of Aramchol for liver and GI cancers
EoCene Ltd. (EOCN) · Mon 16 Nov 2026
Corbus starts registrational TEMPO-1 trial of Nectin-4 ADC sutantatug envedotin in OPSCC
🇺🇸 Corbus Pharmaceuticals Holdings, Inc. (CRBP) · Mon 16 Nov 2026
Adagio Medical's VT ablation PMA remains under FDA review as board explores strategic alternatives
🇺🇸 Adagio Medical Holdings, Inc. (ADGM) · Mon 16 Nov 2026